Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
A phase 1/2 trial of AZD5335, Saruparib, Bevacizumab in ovarian cancer and endometrial cancer, run by AstraZeneca, now recruiting.
Overview
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT05797168 by AstraZeneca, with 602 participants planned, started 2023-06-05 and due to reach its primary completion in 2028-08-04. Interventions recorded: Torvutatug samrotecan, Saruparib, Bevacizumab, Carboplatin, Palacaparib. Conditions listed: Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
Shares Palacaparib, Saruparib, Endometrial cancer, AstraZeneca.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares AZD5335, AstraZeneca, Ovarian cancer.
- TrialStudy of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Shares Bevacizumab, Endometrial cancer, AstraZeneca, Carboplatin.
- TrialStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
Shares Palacaparib, AstraZeneca.
- TrialStudy of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Shares Saruparib, AstraZeneca, Carboplatin, Ovarian cancer.
- TrialDESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC
Shares Endometrial cancer, AstraZeneca, Carboplatin, Pembrolizumab.
- TrialA Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
Shares Bevacizumab, Carboplatin, Ovarian cancer, Pembrolizumab.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares Saruparib, AstraZeneca.